Further, a previously described dual inhibition of MAPK signaling with chemicals of SCH772984 and XMD8-9224, which induced a dramatic degradation of c-Myc in KRAS activated cancer cells, can be a qualified strategy for the treatment of PDAC with KRAS activation. Here, KRAS is linked to cancer.